| 31 |
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions |
2024 |
| 32 |
Design and synthesis new dihydropyrimidine derivatives with cytotoxic effect as dual EGFR/VEGFR-2 inhibitors |
2024 |
| 33 |
Design and synthesis new indole-based aromatase/iNOS inhibitors with apoptotic antiproliferative activity |
2024 |
| 34 |
Design and synthesis of new 1, 2, 4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors |
2024 |
| 35 |
Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition |
2024 |
| 36 |
Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases |
2024 |
| 37 |
Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives |
2024 |
| 38 |
Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors |
2024 |
| 39 |
Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors |
2024 |
| 40 |
Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors |
2024 |
